Clinical trial
Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation…
NCT00353964 · Evolutec Group, Industry · Unknown status
Key facts
| NCT number | NCT00353964 |
|---|---|
| Title | Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery |
| Official title | A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery |
| Lead sponsor | Evolutec Group, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ocular Inflammation |
| Intervention type | Drug |
| Interventions | rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle |
| First posted | Jul 19, 2006 |
| Last update posted | Jul 28, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: